BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...to nearly $280 million.Another CAR T company, JW Therapeutics...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...Staff JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics...
...polyangitis and microscopic polyangiitis.TARGETSC5AR1 (C5AR; CD88) - Complement receptor 5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...value to nearly $9.9 billion after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics...
...discover mAbs with Mount Sinai Health System under a March deal. Elizabeth S. Eaton Inhibrx Inc. Harmony Biosciences Harbour BioMed JW Therapeutics...
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Bristol Myers Squibb Co. Genentech Big Health JW Therapeutics Lyell Neurology Insomnia...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...Investors Back Cullinan’s Asset-Centric Approach” ). Cell therapy co JW gets TCR tech in takeout JW Therapeutics...
...receptor tyrosine kinase BioCentury Staff Elizabeth S. Eaton, Staff Writer Taletrectinib (AB-106, DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics...
...maintain efficacy in the immunosuppressive microenvironment of solid tumors. Under Tuesday’s licensing agreement, Acepodia granted JW Therapeutics...
...Patrick Yang and Sonny Hsiao University collaborators: University of California Berkeley Corporate partners: BioMab Inc., JW Therapeutics...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...“HKEX’s Biotech Chapter Shows All the Signs of a Sustainable Market” ). JW’s megaround JW Therapeutics...
...from Juno. Targets PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor JWCAR029 Roche Innovent Biologics Inc. JW Therapeutics CD19...
BioCentury | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Inc., now a subsidiary of Celgene Corp. (NASDAQ:CELG), and WuXi AppTec Co. Ltd. (Shanghai:603259) launched JW Biotechnology (Shanghai...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...Ltd. Shanghai, China $150.0 6 Dimensions Capital , Boyu Capital , Temasek Preclin Cancer 2018 JW Therapeutics...
...Ltd. raised $150 million in a series A round in July and CAR T play JW Therapeutics...
...Mass. Hope Medicine Inc., Beijing, China Institut Curie, Paris, France Johns Hopkins University, Baltimore, Md. JW Therapeutics...
Items per page:
1 - 10 of 22
BioCentury | Dec 19, 2020
Product Development

Chinese biotechs test the waters of novel technology platforms

...to nearly $280 million.Another CAR T company, JW Therapeutics...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

...Staff JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics...
...polyangitis and microscopic polyangiitis.TARGETSC5AR1 (C5AR; CD88) - Complement receptor 5A BC Staff LUMEVOQ (GS010, RAAV2/2_ND4) Avacopan (CCX168, C5aR inhibitor) JW Therapeutics...
BioCentury | Aug 20, 2020
Finance

Inhibrx, Harmony debut on NASDAQ as JW, Harbour line up on HKEX

...value to nearly $9.9 billion after raising $213.3 million (see “Big Post-IPO gain for CureVac”).Separately, JW Therapeutics...
...discover mAbs with Mount Sinai Health System under a March deal. Elizabeth S. Eaton Inhibrx Inc. Harmony Biosciences Harbour BioMed JW Therapeutics...
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Bristol Myers Squibb Co. Genentech Big Health JW Therapeutics Lyell Neurology Insomnia...
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...Investors Back Cullinan’s Asset-Centric Approach” ). Cell therapy co JW gets TCR tech in takeout JW Therapeutics...
...receptor tyrosine kinase BioCentury Staff Elizabeth S. Eaton, Staff Writer Taletrectinib (AB-106, DS-6051, DS-6051b) AnHeart Therapeutics Inc. Daiichi Pharmaceutical Co. Ltd. JW Therapeutics...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...The platform, which has the potential for cost savings compared with CAR T therapy, led JW Therapeutics...
...maintain efficacy in the immunosuppressive microenvironment of solid tumors. Under Tuesday’s licensing agreement, Acepodia granted JW Therapeutics...
...Patrick Yang and Sonny Hsiao University collaborators: University of California Berkeley Corporate partners: BioMab Inc., JW Therapeutics...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...“HKEX’s Biotech Chapter Shows All the Signs of a Sustainable Market” ). JW’s megaround JW Therapeutics...
...from Juno. Targets PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor JWCAR029 Roche Innovent Biologics Inc. JW Therapeutics CD19...
BioCentury | Jun 25, 2019
Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
BioCentury | Jun 14, 2019
Company News

Tessa forms JV with biohub to bring its cell therapies to China

...Inc., now a subsidiary of Celgene Corp. (NASDAQ:CELG), and WuXi AppTec Co. Ltd. (Shanghai:603259) launched JW Biotechnology (Shanghai...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...Ltd. Shanghai, China $150.0 6 Dimensions Capital , Boyu Capital , Temasek Preclin Cancer 2018 JW Therapeutics...
...Ltd. raised $150 million in a series A round in July and CAR T play JW Therapeutics...
...Mass. Hope Medicine Inc., Beijing, China Institut Curie, Paris, France Johns Hopkins University, Baltimore, Md. JW Therapeutics...
Items per page:
1 - 10 of 22